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Abstract
Introduction
Despite  high  diabetes  rates  among  Canadian  First 
Nation people, little is known about their cardiovascular 
disease risk. Our aim was to describe the apolipoprotein 
profile with respect to cardiovascular risk in a Canadian 
First Nation community.
Methods
In 2003, a representative sample of adult members of a 
Manitoba First Nation (N = 483) participated in a screen-
ing  study  for  diabetes  and  diabetes  complications.  We 
assessed their cardiovascular risk factors.
Results
Sixty percent of women were at increased cardiovascular 
risk because of low apolipoprotein A1 (apoA1) levels, com-
pared with 35% of men. The proportion of women with low 
apoA1 levels decreased with age, but the proportion with 
low high-density lipoprotein levels remained stable across 
age groups. Both apoB and apoA1 were significantly asso-
ciated  with  obesity  when  age,  sex,  diastolic  blood  pres-
sure, homocysteine, diabetes, and insulin resistance were 
controlled for.
Conclusion
Apolipoprotein and lipid profiles in this First Nation pop-
ulation suggest high cardiovascular risk. Future research 
should  characterize  the  lipoprotein  particle  size  in  this 
population.
Introduction
In recent years, the prevalence of cardiovascular disease 
among  Aboriginal  people  in  Canada  has  been  increas-
ing and is now higher than the prevalence among non-
Aboriginal  people.  In  a  random  sample  of  Canadian 
Aboriginal people, the prevalence of cardiovascular disease 
was 18%, compared with 8% in Canadians of European 
descent (1).
Apolipoprotein A1 (apoA1) is the major protein of high-
density lipoprotein (HDL), and apoB is among the major 
proteins of very low-, low- (LDL), and intermediate-density 
lipoproteins. Because of their associations with the respec-
tive lipoproteins, apoA1 is inversely and apoB is positively 
associated with cardiovascular risk (2). In fact, evidence 
suggests  that  apoA1  and  apoB  are  better  predictors  of 
heart disease risk than are HDL and LDL cholesterol lev-
els (3-5). Apolipoproteins may also offer advantages over 
lipoprotein  cholesterol  measurements  because  they  are 
direct measurements, whereas LDL, for example, is calcu-
lated from other lipoproteins from a fasting blood sample.
Despite  the  high  rate  of  diabetes  and  cardiovascular 
disease among Canadian Aboriginal people, little research 
has  gone  beyond  examining  traditional  risk  factors.  In 
addition, research has been mostly based on chart review, 
and  the  few  population-based  studies  that  have  been 
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conducted  have  been  limited  to  a  single  First  Nation   
community (6-8). Our objective was to describe the apo-
lipoprotein profile and its relationship to cardiovascular 
risk factors in a Canadian First Nation community.
Methods
We  conducted  this  study  with  data  from  a  larger   
community-based  screening  study  on  diabetes  compli-
cations (9). The sample of 483 men and women from a 
Manitoba First Nation was representative in terms of age 
and sex. Eligible participants (n = 1,356) were nonpreg-
nant adults aged 18 years or older who were registered 
Indians and lived in the community. The community is 
approximately 200 km northwest of Winnipeg, Manitoba. 
Data were collected from January through December 2003, 
and each participant had all of his or her data collected on 
the same day. Further details on the study can be found 
elsewhere (9). The study was approved by the University 
of Manitoba Health Research Ethics Board.
A registered nurse collected a fasting blood sample, and 
we assessed levels of plasma glucose, insulin, triglyceride, 
HDL cholesterol, LDL cholesterol, total cholesterol, total 
apoB, and apoA1. The nurse also measured blood pres-
sure, urinary albumin and creatinine levels, and anthropo-
metric characteristics (9). To assess insulin resistance, we 
used the homeostatic model assessment with glucose and 
insulin results in the following equation: (insulin [pmol] × 
0.139) × (glucose [mmol/L]/22.5). Risk factors assessed in 
this study are defined in Table 1.
We analyzed all data by using SPSS version 16.0 for 
Windows (IBM, Chicago, Illinois). We compared plasma 
lipid levels by using t tests and Mann-Whitney U nonpara-
metric tests. We compared differences in apolipoprotein 
levels by cardiovascular risk factors by using both t tests 
and Mann-Whitney U tests for variables with a nonnor-
mal distribution or unequal variances. We used χ2 tests 
to detect differences in risk for cardiovascular disease by 
apolipoprotein category. Tests were 2-tailed, and P values 
<.05  were  considered  significant.  To  determine  linear 
trends for mean apolipoprotein values by age group, we 
used  1-way  analysis  of  variance  with  linear  contrast. 
We estimated odds ratios for obesity by using backward 
stepwise  multivariate  logistic  regression.  We  included 
variables in the model that were significantly associated 
with obesity in bivariate analyses. Those variables were 
age, sex, ever having smoked, systolic and diastolic blood 
pressure,  presence  of  diabetes,  triglyceride  level,  apoA1 
level, apoB level, insulin resistance, homocysteine level, 
and microalbuminuria.
Results
Risk  for  cardiovascular  disease  was  high  according 
to  traditional  cardiovascular  risk  factors  such  as  HDL 
cholesterol and triglyceride levels (Table 2). Rates of obe-
sity, diabetes, hypertension, and microalbuminuria in this 
population were also high (Table 3).
Significantly more women than men had apoA1 values 
that indicated cardiovascular risk (60% vs 35%; P < .001). 
Almost 18% of men and 12% of women had apoB values 
that  indicated  cardiovascular  risk,  but  the  difference 
was not significant. The proportion of participants with 
increased risk according to the apoB:apoA1 ratio was 54% 
for men and 57% for women, and the difference did not 
reach significance.
Mean  apoB  concentrations  and  the  apoB:apoA1  ratio 
were significantly higher in men and participants with any 
cardiovascular risk factor (Table 3). Mean apoA1 concen-
trations were lower in patients with most cardiovascular 
risk factors, but the difference did not reach significance in 
patients with diabetes, hypertension, microalbuminuria, 
or cardiometabolic risk.
Cardiovascular risk tended to increase with age (Tables 
4 and 5). We found a significant linear trend for age in men 
for apoB and apoB:apoA1 ratio. We also found a significant 
and positive linear trend for age in women for apoB and 
apoB:apoA1 ratio. Conversely, cardiovascular risk accord-
ing to apoA1 decreased with age among women, and mean 
apoA1 levels increased with age. HDL cholesterol levels 
did not significantly increase or decrease with age among 
women (data not shown).
The final logistic model for presence of obesity included 
age, sex, diastolic blood pressure, diabetes, homocysteine, 
insulin  resistance,  apoA1,  and  apoB.  A  person  with  an 
apoA1 value of 1.14 g/L was 1.2 times as likely to be obese 
as was a person with an apoA1 of 1.20 g/L. Furthermore, 
the odds of obesity were 1.35 times as high for a person 
with an apoB level of 1.00 g/L as for a person with a level 
of 0.80 g/L.VOLUME 8: NO. 1
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Discussion
According  to  plasma  lipid  levels  and  apolipoprotein 
profiles, the risk for cardiovascular disease is high among 
Canadian First Nation people. The abnormal plasma apo-
lipoprotein concentrations we found are consistent with 
the high prevalence of obesity and diabetes in the commu-
nity. Generally, participants had low HDL cholesterol, low 
apoA1, and high triglyceride levels, which typically coexist 
in people with insulin resistance.
The average lipid profile in the study community differed 
dramatically  from  that  of  the  US  population  in  general 
(11), most likely because of the high prevalence of diabe-
tes  in  the  community.  For  example,  mean  plasma  LDL 
cholesterol  levels  among  study  participants  were  lower 
than those among NHANES participants for both sexes. 
However, plasma HDL cholesterol levels were lower and 
plasma triglyceride levels were much higher among our 
study  participants  than  among  the  general  American 
population. Compared with Australian Aboriginal people 
and  Torres  Strait  Islanders  (12),  our  study  participants 
had slightly lower triglyceride and higher HDL cholesterol 
levels.  However,  these  levels  are  still  worse  than  those 
among  other  Canadian  Cree-Ojibwa  Indians,  Inuit,  or 
non-Aboriginal people, as assessed in the early 1990s (13). 
In addition, triglyceride and HDL cholesterol levels were 
higher and LDL cholesterol levels were lower in the study 
community  than  among  another  Canadian  Aboriginal 
community (1); the other Aboriginal community, however, 
included  only  people  aged  35  to  75  years,  whereas  our 
study sample included people aged 18 years or older, and 
the mean age was 38 years. Neither our lipid values nor 
the others described in this paragraph were age- or sex-
standardized.
Paradoxically, the proportion of women with low apoA1 
levels (higher cardiovascular risk) significantly decreased 
with age, and mean apoA1 levels had a significant positive 
linear trend with older age. The change in apoA1 levels 
by  age  in  women  seems  to  indicate  more  dyslipidemia 
in  younger  women.  However,  the  proportion  of  women 
with HDL cholesterol levels that indicated increased risk 
remained stable across age groups. Therefore, for the same 
HDL  cholesterol  levels,  older  women  (≥50  y)  had  lower 
apoA1 levels than did younger women (<50 years). This 
phenomenon may reflect a shift in HDL particle size in the 
older age groups, in which the proportion of small, dense 
HDL particles increases relative to large HDL particles. 
This explanation is further supported by the fact that the 
prevalence of diabetes increased with increasing age in 
our study.
Despite a likely genetic susceptibility to diabetes and its 
comorbidities in this First Nation community, we hypothe-
size that much of the dyslipidemia can be attributed to poor 
diet and inactivity. In the past, other indigenous communi-
ties, such as the Greenland Inuit, actually had more favor-
able lipid profiles than did nonindigenous people, most like-
ly because of their traditional lifestyle (14). When compared 
with  Danish  controls,  the  Inuit  had  significantly  higher 
apoA1 and significantly lower apoB, LDL cholesterol, total 
cholesterol, and triglyceride levels. Although apoA1 levels 
were significantly higher among the Inuit, HDL cholesterol 
levels were not, which indicates potential differences in the 
types of HDL between the 2 groups (differences in particle 
size). The Inuit may have a disproportionate number of 
atherogenic small, dense HDL particles, as opposed to the 
more  beneficial  large  HDL  particles,  which  is  what  we 
hypothesize in our study community, particularly among 
women. In a Canadian Oji-Cree First Nation community, 
although apoA1 levels were significantly lower among men 
with hypertriglyceridemic waist, apoA1 levels were actu-
ally  nonsignificantly  higher  among  women  with  hyper-
triglyceridemic waist (15). This apoA1 sex difference may 
partially explain the higher risk for coronary heart disease 
for women with diabetes than men with diabetes (16).
A preponderance of small, dense LDL and small HDL 
particles  is  associated  with  obesity  (17),  increased  risk 
of  coronary  artery  disease  (18),  and  insulin  resistance, 
regardless of diabetes status (19). Low HDL cholesterol 
concentrations among people with diabetes may indicate 
a specific reduction in large HDL particles (as well as a 
possible increase in small HDL particles), which may not 
necessarily significantly reduce apoA1 levels (19). In our 
study, because of the high rate of diabetes, we suspect that 
the low HDL cholesterol levels reported are due to the loss 
of  large  HDL  particles,  especially  among  older  women. 
Women may also have lower HDL cholesterol levels than 
men in response to obesity (20), so apoA1 levels may also 
differ between men and women in response to obesity.
The apparent conflicting results of apoA1 and HDL cho-
lesterol levels may affect the predictive nature of apoA1 
and the apoB:apoA1 ratio for cardiovascular risk in this 
population. Future research should determine the asso-
ciation of apoA1 and apoB:apoA1 ratio on cardiovascular VOLUME 8: NO. 1
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outcomes in First Nation people with diabetes. The apoB:
apoA1 ratio was found to predict metabolic syndrome in 
nonobese but not obese participants (21), perhaps because 
obese participants are more likely to have diabetes. Mean 
apoA1 values were virtually identical in our study com-
munity,  regardless  of  diabetes  status,  but  mean  HDL 
cholesterol levels were significantly lower in participants 
with diabetes. This finding supports the notion of an HDL 
profile of mostly small HDL particles in people in the com-
munity, which would keep plasma HDL levels low while 
increasing apoA1 levels.
Our study has several limitations. Although we cannot 
say whether the sample was completely representative of 
the population, it was representative according to age and 
sex and did not consist of those in the poorest health. Only 
105 of the 275 community members with previously diag-
nosed diabetes participated. In addition, 3 of 10 commu-
nity members with amputations and none of 15 members 
with end-stage renal disease participated. We also did not 
assess lipoprotein particle size and the distribution of sizes 
among the various types of lipoproteins. Finally, because 
of the cross-sectional nature of the data, no outcome data 
are available.
In conclusion, this community is at high cardiovascular 
risk,  according  to  both  plasma  lipid  and  apolipoprotein 
profiles. Much of this risk is mediated by the high number 
of community members with diabetes and obesity and the 
associated changes in lipoprotein profile. More data regard-
ing lipoprotein particle size and the distribution of small, 
medium, and large HDL and LDL particles are needed to 
confirm our hypotheses, but these preliminary data can be 
used to guide interventions that reduce the prevalence of 
chronic disease in Canadian First Nation people.
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Tables
Table 1. Risk Factors Assessed in a Study of Cardiovascular Risk in a Canadian First Nation, 2003
Risk Factor
Definition
Men Women
Obesity BMI ≥30.0 kg/m2
High-risk WC WC >102 cm WC >88 cm
Diabetes Self-report diagnosis, taking an oral hypoglycemic agent, or fasting glucose ≥7.0 mmol/L
Hypertension Self-report of diagnosis, SBP >10 mm Hg, or DBP >90 mm Hg
Dyslipidemia Fasting plasma TG ≥1.7 mmol/L and fasting 
plasma HDL cholesterol ≤1.03 mmol/L
Fasting plasma TG ≥1.7 mmol/L and fasting plasma 
HDL cholesterol ≤1.3 mmol/L
Microalbuminuriaa ACR >2.0 mg/mmol ACR >2.8 mg/mmol
Metabolic syndrome Adult Treatment Panel III criteria (10)
Cardiometabolic risk At-risk WC plus plasma TG ≥1.7 mmol/L
Low apoA1 ApoA1 <1.07 g/L ApoA1 <1.22 g/L
High apoB ApoB >1.2 g/L
High apoB:apoA1 ratio () >0.8 >0.7
 
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL, high-density 
lipoprotein; ACR, albumin-to-creatinine ratio; apo, apolipoprotein. 
a Determined by using the Bayer DCA 2000 point-of-care analyzer (Elkhart, Indiana).
Table 2. Plasma Lipid Levels Among 483 Canadian First Nation Adults, 2003
Lipida Men (n = 230), Mean (SD) Women (n = 253), Mean (SD) P Valueb Men and Women, Mean (SD)
Triglyceride, mmol/L
2. (2.) 2.1 (2.0) .86 2.2 (2.)
1.7 (1.1-2.6)c 1.7 (1.2-2.5)c 1.7 (1.2-2.6)c
LDL cholesterol, mmol/L 2.9 (0.9) 2.6 (0.9) <.001 2.7 (0.9)
HDL cholesterol, mmol/L 1.2 (0.) 1.2 (0.) <.0d 1.2 (0.)
Total cholesterol, mmol/L .0 (1.2) .8 (1.1) .07 .9 (1.2)
 
Abbreviations: SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
a Mean LDL and total cholesterol values are provided, although these were not included in the definition of dyslipidemia because their recommended levels 
vary according to other risk factors (http://www.cfpc.ca/english/cfpc/programs/patient%20education/cholesterol/default.asp). 
b Independent t test for differences between sex, unless otherwise noted. 
c Data presented as median (interquartile range) because of skewed distribution; statistical analysis with Mann-Whitney test. 
d Mann-Whitney test (unequal variances).VOLUME 8: NO. 1
JANUARY 2011
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Table 3. Plasma Apolipoprotein Levels by Sex and Risk Factors for Cardiovascular Disease Among 483 Canadian First Nation 
Adults, 2003a
Characteristicb n (%) ApoB (g/L) P Value ApoA1 (g/L) P Value
ApoB:ApoA1 
Ratio P Value
Sex
Men 20 (8) 0.9 (0.28)
.06
1.1 (1.0-1.2)c
.00d
0.8 (0.6-1.02)c
.001d
Women 2 (2) 0.89 (0.26) 1.17 (1.05-1.31)c 0.75 (0.59-0.91)c
Obese
Yes 26 (6) 0.97 (0.96)
<.001
1.13 (0.17)
<.001
0.87 (0.24)
<.001
No 20 () 0.83 (0.79) 1.20 (0.19) 0.71 (0.24)
At-risk waist circumference
Yes 1 (68) 0.96 (0.26)
<.001
1.1 (0.18)
.006
0.8 (0.2)
<.001
No 11 (2) 0.82 (0.26) 1.20 (0.18) 0.70 (0.23)
Diabetes
Yes 10 (29) 1.0 (0.29)
<.001
1.16 (0.19)
.92
0.91 (0.26)
<.001
No 343 (71) 0.86 (0.2) 1.17 (0.18) 0.75 (0.23)
Hypertension
Yes 201 () 0.99 (0.28)
<.001
1.18 (0.19)
.10
0.85 (0.27)
<.001
No 271 (57) 0.86 (0.2) 1.1 (0.18) 0.76 (0.23)
Microalbuminuria
Yes 9 (20) 1.01 (0.81-1.26)c
<.001d
1.15 (0.17)
.9
0.90 (0.26)
<.001
No 372 (80) 0.86 (0.68-1.0)c 1.17 (0.18) 0.77 (0.24)
Cardiometabolic risk
Yes 212 () 1.0 (0.2)
<.001
1.16 (0.19)
.
0.9 (0.2)
<.001
No 2 () 0.80 (0.2) 1.17 (0.18) 0.70 (0.21)
Dyslipidemia
Yes 1 (2) 1.0 (0.90-1.19)c
<.001d
1.07 (0.98-1.18)c
<.001d
0.98 (0.2)
<.001
No 28 (68) 0.81 (0.6-1.01)c 1.19 (1.09-1.1)c 0.72 (0.22)
Metabolic syndrome
Yes 22 () 1.02 (0.26)
<.001
1.13 (0.17)
<.001
0.91 (0.75-1.05)c
<.001d
No 223 (47) 0.80 (0.2) 1.20 (0.18) 0.6 (0.-0.80)c
 
Abbreviation: apo, apolipoprotein. 
a Values for apoA1, apoB, and apoB:apoA1 ratio are given as mean (standard deviation), and differences were assessed by using independent-samples t tests, 
unless otherwise noted. 
b Definitions for characteristics are provided in Table 1. Data were not available for all participants for every characteristic. 
c Results reported are median (interquartile range) because of skewed distribution. 
d Mann-Whitney U (nonparametric) test.VOLUME 8: NO. 1
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Table 4. Plasma Apolipoprotein Levels by Sex and Age Among 481a Canadian First Nation Adults, 2003
Sex and Age, y Mean (SD) ApoB P Valueb Mean (SD) ApoA1 P Valueb
Mean (SD) ApoB:
ApoA1 Ratio P Valueb
Men (n = 229)
18-29 (n = 72) 0.79 (0.26)
<.001
1.12 (0.1)
.12
0.71 (0.25)
<.001
0-9 (n = 6) 0.9 (0.2) 1.1 (0.1) 0.8 (0.2)
0-9 (n = 9) 1.09 (0.26) 1.1 (0.16) 0.97 (0.24)
≥50 (n = 43) 1.01 (0.2) 1.17 (0.17) 0.88 (0.2)
Women (n = 252)
18-29 (n = 70) 0.78 (0.24)
<.001
1.1 (0.20)
.0
0.69 (0.22)
.001
30-39 (n = 78) 0.89 (0.22) 1.20 (0.17) 0.75 (0.21)
0-9 (n = 9) 0.96 (0.27) 1.21 (0.21) 0.81 (0.2)
≥50 (n = 45) 0.99 (0.29) 1.22 (0.22) 0.8 (0.28)
 
Abbreviations: SD, standard deviation; apo, apolipoprotein. 
a For 2 participants, the blood sample was insufficient to assess apoA1 and apoB; priority was given to measuring the other plasma lipids (total cholesterol, 
low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride). 
b Analysis of variance with linear contrast.
Table 5. Canadian First Nation Adults at Risk for Cardiovascular Disease by Plasma Apolipoprotein Levels, 2003 (N = 481)a
Sex and Age, y n (%) ApoB P Valueb n (%) ApoA1 P Valueb
n (%) ApoB:ApoA1 
Ratio P Valueb
Men (n = 229)
18-29 (n = 72) 5 (7)
.00
2 ()
.87
20 (29)
<.001
0-9 (n = 6) 10 (1) 24 (37) 37 (57)
0-9 (n = 9) 1 (1) 18 (37) 0 (82)
≥50 (n = 43) 10 (2) 1 () 2 (8)
Women (n = 252)
18-29 (n = 70) 5 (7)
.006
52 (74)
.006
0 ()
.01
30-39 (n = 78) 6 (8)  ()  (8)
0-9 (n = 9) 10 (17) 37 (63) 8 (6)
≥50 (n = 45) 10 (22) 20 () 29 (6)
 
Abbreviation: apo, apolipoprotein. 
a Cutoffs for increased cardiovascular risk are shown in Table 1. For 2 participants, the blood sample was insufficient to assess apoA1 and apoB; priority was 
given to measuring the other plasma lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride). 
b χ2 Test with linear association.